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Background: To investigate the effects of RNA interference-mediated downregulation of Human Solute Carrier
Family 35 member F2 (SLC35F2) expression on the biological behavior of lung cancer H1299 cells.
Methods: The lentiviral vector of small interfering RNA targeting SLC35F2 was introduced into H1299 cells by
liposome-mediated transfection. Expression of the SLC35F2 protein was measured by western blot. The proliferation
of H1299 cells was determined by Cell Counting Kit-8 assay. The migration of H1299 cells was measured by
Transwell migration assay. Cell cycle analysis used fluorescence-activated cell sorting.
Results: SLC35F2 expression was markedly downregulated in H1299 cell clone (transfected with the lentiviral vector
harboring small interfering RNA targeting SLC35F2). Proliferation decreased significantly compared with that of
non-transfected H1299 cells. Transwell migration assay showed that fewer cells moved through the artificial basement
membrane compared with untransfected H1299 cells (38.3 ± 5.7 vs. 113.5 ± 8.5, P < 0.05). The cell cycle of H1299 cells
was changed, the percentage of H1299 cells in S and G2/M phases being significantly decreased compared with
untransfected H1299 cells (S phase: 15.3% ± 3.0% vs. 27.0% ± 5.4%, P > 0.05; G2/M phase; 3.0% ± 1.1% vs. 10.5% ± 1.7%,
P < 0.05), whereas the percentage of H1299 cells in G0/G1 phase increased markedly (81.7% ± 4.0% vs. 62.5% ± 1.9%,
P < 0.05).
Conclusion: RNA interference-mediated downregulation of SLC35F2 expression by lentiviral vector can attenuate the
proliferation, migration and invasion of H1299 cells.
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RNA interference (RNAi) is an evolutionarily conserved
process whereby double-stranded RNA (dsRNA) induces
a sequence-specific degradation of homologous mRNA,
leading to post-transcriptional gene silencing. This involves
cleavage of dsRNA into short (21–23 nt) small interfering
RNAs (siRNAs) with characteristic 2 nt 30-overhanging
ends, which is mediated by Dicer.
Stankovic et al. [1] initially reported on Human Solute
carrier family 35 member F2 (SLC35F2) in ataxia
telangiectasia. The SLC35F2 gene is located in the long
arm of human 11 chromosome. RAB39, a member of the
cancer gene Ras family, is close to SLC35F2 in the same
chromosomal position (11q22). It participates in the
construction of human blood–brain barrier and has higher* Correspondence: jwangmd@yahoo.com
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reproduction in any medium, provided the orexpression in adult salivary glands [2,3]. Knowledge about
the functions of the SLC35F2 gene is currently lacking.
Shen et al. [4] found that the SLC35F2 gene might be
related to the incidence of lung cancer by differential
screening. The Department of Thoracic Surgery in Peking
University People's Hospital reported that the expression of
the SLC35F2 protein is obviously higher in non-small-cell
lung carcinoma (NSCLC) tissue than in normal tissues near
the tumor, indicating that SLC35F2 might be a potential
oncogene [5,6]. To develop further studies on the biological
functions of SLC35F2, we constructed SLC35F2 recom-
binant RNAi lenti-virus vectors, and got transfected
H1299 lung cancer cells in which the expression of
SLC35F2 was stably inhibited by RNAi [7]. Here we are to
investigate the effect of the SLC35F2 gene on the
biological behavior of human lung cancer cell line H1299.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Construction and validation of lentiviral vector,
establishment of SLC35F2 silencing H1299 cell line
The lentiviral vector of siRNA targeted against SLC35F2
(SLC-siRNA) was constructed and transfected H1299
cells successfully. We got the H1299 cell lines which
were transfected by lentiviral vector harboring specific
siRNA (SLC-si) and lentiviral vector harboring control
siRNA (SLC-nc) [7]. We could see both of the transfected
H1299 cell lines with green light under an inverted fluores-
cence microscope, confirming the transfection of lentiviral
vector to cell genome and its stable expression (Figure 1).
Compared with control group, the SLC35F2 expression
was decreased significantly both in RNA and protein level,
as described in our study before [7].Effect of SLC35F2 on the proliferation capacity of H1299
lung cancer cells
The effect of SLC35F2 silencing on the proliferation of
H1299 lung cancer cells was determined by CCK-8 assay.
As shown in Figure 2, after 7 days’ culture, the in vitro
growth rate of the SLC35F2 suppression group was lower
than that of the non-transfected group (P < 0.05). But no
significant difference was found between the negative
control group and the non-transfection group (Figure 2).
Therefore, in vitro cell growth ability was correlated with
SLC35F2 expression.Effect of SLC35F2 on the migration capacity of H1299 cells
After the SLC35F2 gene had been inhibited, the migration
capacity of H1299 declined, with the cell population
coming through the artificial membrane being less than
that of the non-transfected group (38.2 ± 3.7 vs. 103.8 ± 8.5,
P < 0.05). No statistical difference in trans-membrane
cells was found between the negative control group and
the non-transfected group (96.8 ± 9.4 vs. 103.8 ± 8.5,
P > 0.05, Figure 3).Figure 1 Expression of green fluorescence protein in H1299 cells afte
(X100). A: common microscope B: fluorescence microscope. We could see
fluorescence microscope 14 days after the transfection, confirming the tranEffect of SLC35F2 on the invasion capacity of H1299 cells
The tumor cell invasion through the ECM is an important
step in tumor metastasis. ECMatrix serves as a reconstituted
basement membrane matrix of proteins. The number of
cells migrating to ECMatrix was counted. Compared with
non-transfected cells, SLC35F2 silencing cells decreased
invasiveness significantly (16.5 ± 1.8 vs. 64.5 ± 4.8, P < 0.05).
No statistical difference was found between the negative
control group and the non-transfected group (58.4 ± 5.2
vs. 64.5 ± 4.8, P > 0.05).
Effect of SLC35F2 on the cell cycle of H1299 cells
Compared with untransfected cells, silencing of SLC35F2
caused an accumulation of cells in the G0/G1 phase
(81.6% ± 4.0% vs. 62.5% ± 1.9%, P < 0.05), while reducing the
number of cells in S and G2/M phases(S Stage: 15.3% ±
3.0% vs. 27.0% ± 5.4%, P > 0.05; G2/M Stage: 3.0% ± 1.1%
vs. 10.5% ± 1.7%, P < 0.05, Figure 4).
Discussion
The SLC35 gene, which encodes nucleotide sugar trans-
porter protein, is a hydrophobin consisting of 320 to 400
amino acid residues. It has 6 members: SLC35A-F. SLC35
A-E proteins are located in the endoplasmic reticulum
(ER) and Golgi body, with about 10 transmembrane helices.
They can transport nucleotide sugar into the Golgi body
and/or ER. As sugar donors, they are used to synthesize
glycoside-protein, glycolipid, and polyose by glycosyl
transferase [8]. As reported, this type of nucleotide sugar
transporter is related to neoplasm metastasis, cellular
immunity, organ development, and morphological charac-
teristics [9]. According to the study before, SLC35A1
transports CMP-Sia, SLC35A2 transports UDP-Gal, and
SLC35A3 transports UDP-GlcNAc [8,10]. SLC35C1 can
encode a GDP-Fuc transporter protein [8], SLC35D1
transports UDP-GlcA/UDP-GalNac [11], and SLC35B3
encoded 3′-phosphoadenosine 5′-sulfate transporter protein
which is related to the synthesis of sulfated proteoglycanr stable transfected under inverted fluorescence microscope
the transfected H1299 cell lines with green light under an inverted
sfection is successful and stable.
Figure 2 Growing curves of the different groups. After 7 days’
culture, the in vitro growth rate of the SLC35F2 suppression group
(1299-siRNA) was lower than that of the non-transfected group
(1299-NC) (P < 0.05). But no significant difference was found
between the negative control group and the non-transfection
group (1299).
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(F1-F5), but their functions remain unclear. Matsuyama
et al. [13] reported that there was some difference of
SLC35F2 expression between 5-fluorouracil-sensitive and
resistant tumors.Figure 3 Migration capacity of different groups of H1299 cells. A: non
(X100). D Histogram of migration capacity of different groups of H1299 cel
C is much less than that of the group A and B. No significant difference wStudies on the functions of the SLC35F2 gene are
currently lacking. The SLC35F2 gene is located in the
long arm of human 11 chromosome. RAB39, a member
of the cancer gene Ras family, is close to SLC35F2 in
the same chromosomal position (11q22). Our previous
study showed that the SLC35F2 gene expressed differently
in human lung squamous carcinoma and normal tissue
nearby. SLC35F2 gene expression is higher in NSCLC
tissue than in normal lung tissues near the tumor. So we
conjecture SLC35F2 may participate in the occurrence
and development of NSCLC, and thus may be a potential
oncogene [5,6].
Here we used RNAi to silence SLC35F2 in H1299 cell
line, and studied the effect of the SLC35F2 gene on the
biological behavior of lung cancer cell line. Proliferation
rate was slowed down after silencing SLC35F2, and H1299
cells were blocked in G0/G1 phase, with the number in S
phase being reduced significantly. The reason might be
that with the reverse transport of nucleotide sugar inside
the cells being affected, the synthesis of materials required
for proliferation became restricted. The migration and
invasion capacities of the cells were reduced after the
SLC35F2 gene was inhibited, which suggests that SLC35F2
plays an important role in the migration and invasion of
lung cancer cells to peripheral tissues.
For the first time, we have identified the influence of
SLC35F2 on the biological behavior of H1299 lung cancer
cell line in this study. The results are consistent with our-transfected group; B: negative control group; C: transfected group
ls. The number of the cells coming through the membrane in group
as seen between group A and B.
Figure 4 Effect of SLC35F2 on the cell cycle of H1299 cells. A: non-transfection group; B: transfection group. Compared with untransfected
cells, silencing of SLC35F2 caused an accumulation of cells in the G0/G1 phase, while reducing the number of cells in S and G2/M phases. (Here
we just show one of the results, all of the experiments measuring cell cycle were performed three times to ensure reproducibility of results, and
we got the mean as the final result).
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tential oncogene in lung cancer. These results suggest
that SLC35F2 has an important role in the occurrence,
development, and migration of lung cancer. SLC35F2 might
be a potential target for lung cancer therapy in the future.Conclusions
RNA interference-mediated downregulation of SLC35F2
expression by lentiviral vector can attenuate the prolifera-
tion, migration and invasion capacities of H1299 cells,
which suggests that SLC35F2 may be a potential oncogene
of lung cancer.Materials and methods
Cell line and cell culture
Human lung squamous cell carcinoma H1299 cell
was purchased from Cell Bank of Chinese Academy
of Sciences (Shanghai, China), and was cultured in DMEM
supplemented 5% fetal bovine serum (Hyclone), and 1%
penicillin/streptomycin (Life Technologies).Construction of SLC35F2 RNAi vector and transfection
Oligonucleotide sequence of SLC35F2 specific siRNA is
pSC-1: CTCTTTCTGTTTGGCTATA. SLC35F2 RNAi
lentiviral vector construction, virus infection, cloning
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and western blot were carried out as described previously
[7]. The forward primer 5'- TAACCAGTGTCCAGCTTT
TGGA -3', and the reverse primer 5'- CCATGGTTCCT
ACACCCAACA -3' are used for amplifying SLC35F2.
Cell growth assay
Dispense 200 μl of H1299 cells suspension (2,000 cells/well)
in a 96-well plate. Incubate the plate for 1–7 d at 37°C in
an atmosphere of 5% CO2 in air. Add 20 μl of CCK-8
solution to each well of the plate and incubate the plate
for additional 4 h at the same condition. Then measure
the absorbance at 450 nm using a microplate reader.
The absorbance value indicating proliferative capacity.
An average value from 3 wells was obtained for each
group of H1299 cells to get the growth curve.
Migration and invasion assays
H1299 cells of nontransfected group, SLC35F2 siRNA
lentiviral vector transfected group, and siRNA-C (control)
transfected group were detached from culture plates in the
absence of trypsin using Hank’s buffered saline solution
(HBSS)/5 mM EDTA/25 mM Hepes pH 7.2 (Mediatech).
Cells then were washed twice in DMEM and resuspended
at a density of 2.5 × 105/ml in DMEM; 200 μl of the cell
suspension was added to the upper chamber of an 8 μm
pore size Transwell insert (Costar) in triplicate. DMEM
culture solution (500 μl) containing 10% fetal bovine serum
was added to the lower chamber of each well and
incubated for 12 h at 37°C. Cells were fixed with 0.025%
glutaraldehyde (Sigma Aldrich) in PBS, stained in 0.1%
crystal violet, and nonmigratory cells on the upper surface
of the membrane were removed. Membranes were mounted
on a microscope slide, and migrated cells were counted in
five random high-power fields.
Invasion assays were carried out in a similar manner
to migration assays. Transwell inserts with 8-μm pores
(Costar) were coated with 200 μl Matrigel (Becton
Dickinson), which was diluted 1:6 in ice-cold DMEM, and
allowed to gel at 37°C. Sub-confluent cell cultures were
detached as described above, resuspended in DMEM, and
1 × 105 cells were seeded in the upper chamber. Culture
plates were incubated for 48 h at 37°C, and the cells fixed,
stained, and counted as described above.
Cell cycle assays
H1299 cells were seeded at 2 × 105 cells/well in 6-well
plates. To analyze the cell cycle distribution, the cells
were collected after 24 h incubation and washed with PBS.
The cells were fixed in 70% ethanol and stored overnight
at 4°C. For analysis, the cells were transferred into PBS
and incubated with Ribonuclease A (50 μg/ml) at room
temperature for 5 min. Following incubation, the cells
were treated with 10 μg/ml PI and incubated at 37°C for10 min. Finally, the cells were analyzed using FACS.
1 × 104 cells per experimental condition were analyzed
for fluorescence on a Becton-Dickinson FACScan using
Cell Quest software. All of the experiments measuring cell
cycle were performed three times to ensure reproducibility
of results, and we got the mean as the final result.
Statistical analysis
The software of SPSS version 13.0 for Windows (SPSS
Inc, Chicago, IL, USA) was used for statistical analysis.
Continuous variables were expressed as X ± s. Statistical
analysis was performed with t-test. Differences were con-
sidered statistically significant when P was less than 0.05.
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